{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:27:56Z","timestamp":1783024076902,"version":"3.54.6"},"reference-count":6,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>\n                    Somatostatin receptor (SSTR) imaging is the preferred modality for staging well-differentiated neuroendocrine tumors (NETs) and detecting unknown primary NETs. If SSTR imaging is negative,\n                    <jats:sup>18<\/jats:sup>\n                    F-FDG PET\/CT may be done to rule out tumor heterogeneity. We report a case of a 36-year-old woman with a well-differentiated grade I NET, who initially presented with severe right hypochondriac pain and vomiting. Standard diagnostic workup with\n                    <jats:sup>68<\/jats:sup>\n                    Ga-DOTANOC followed by\n                    <jats:sup>18<\/jats:sup>\n                    F-FDG PET\/CT was negative; however,\n                    <jats:sup>68<\/jats:sup>\n                    Ga-FAPI-04 PET\/CT demonstrated intense tracer-avid lesions in pancreatic primary and liver metastases.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000006389","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:06:58Z","timestamp":1783022818000},"page":"e720-e723","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Seeing Beyond 68GA-DOTANOC and 18F-FDG PET\/CT: 68GA-FAPI Only Uptake in a Rare Metastatic Well-differentiated Grade I Pancreatic Neuroendocrine Tumor"],"prefix":"10.1097","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3264-9579","authenticated-orcid":false,"given":"Chandra T. R.","family":"Singareddy","sequence":"first","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie K.","family":"Baa","sequence":"additional","affiliation":[{"name":"Medical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreyas R.","family":"Kankara","sequence":"additional","affiliation":[{"name":"Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria F.","family":"Bukelo","sequence":"additional","affiliation":[{"name":"Pathology, St. John\u2019s Medical College Hospital, Bengaluru, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"R1-20260702","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"68Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J Nucl Med"},{"key":"R2-20260702","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1007\/s00259-023-06497-6","article-title":"The inferior performance of [68Ga]Ga-FAPI-04 PET\/CT as a diagnostic and theranostic biomarker in [177Lu]Lu-DOTATATE refractory well-differentiated neuroendocrine tumors","volume":"51","author":"Has Simsek","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R3-20260702","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1097\/RLU.0000000000003490","article-title":"68Ga-FAPI PET\/CT versus 68Ga-DOTATATE PET\/CT in the evaluation of a patient with neuroendocrine tumor","volume":"46","author":"K\u00f6mek","year":"2021","journal-title":"Clin Nucl Med"},{"key":"R4-20260702","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/RLU.0000000000005203","article-title":"68 Ga-DOTATATE and 68 Ga-FAPI imaging in neuroendocrine neoplasms of different grades","volume":"49","author":"Zhou","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R5-20260702","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/RLU.0000000000003763","article-title":"Comparison of 18F-FDG, 68Ga-FAPI, and 68Ga-DOTATATE PET\/CT in a patient with pancreatic neuroendocrine tumor","volume":"46","author":"Cheng","year":"2021","journal-title":"Clin Nucl Med"},{"key":"R6-20260702","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/RLU.0000000000004480","article-title":"Impact of 68 Ga-FAPI-04 PET\/CT on staging and therapeutic management in patients with digestive system tumors","volume":"48","author":"Kosmala","year":"2023","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006389","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:06:59Z","timestamp":1783022819000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":6,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006389","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"assertion":[{"value":"2025-10-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}